A Phase 4 interventional study of Gabapentin and Pregabalin in Healthy, sponsored by Depomed. Completed. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-01.
Sponsored by Depomed · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase 4, double-blind, placebo-controlled, four treatment, four sequence crossover study comparing simulated driving performance, daytime sedation and cognition in healthy volunteers administered therapeutic doses of Gralise® (Treatment A), Neurontin® (Treatment B), Lyrica® (Treatment C) and placebo (Treatment D). All doses were administered under fed conditions.
Depomed is the lead sponsor of 14 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
Drug: Gabapentin
Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Drug: Gabapentin
Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Drug: Pregabalin
Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
Other: Placebo
Also known as: Gralise®, Neurontin®
Also known as: Lyrica®
Also known as: Sugar Pill
Change From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Neurontin®
SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.
Time frame: Baseline and Hour 3 on Day 3
Change From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Lyrica®
SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.
Time frame: Baseline and Hour 3 on Day 3
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Detection Task (DET)
Cogstate - Detection Task (DET) is a simple reaction time test of Psychomotor Function. Higher change from baseline means better performance.
Time frame: Baseline and Hour 3 on Day 3
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Groton Maze Learning Test (GMLT).
Cogstate - The Groton Maze Learning test is a measure Executive Function. Total number of errors made while attempting to learn the same hidden pathway across the consecutive learning trials performed at a single assessment. Lower score means better performance. Higher change from baseline means better performance.
Time frame: Baseline and Hour 3 on Day 3
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Identification Task (IDN).
Cogstate - Identification Task (IDN) assesses Attention. Score is speed of performance (mean of the log10 transformed reaction times for correct responses). Lower score (quicker speed) is better performance. Higher change from baseline means better performance.
Time frame: Baseline and Hour 3 on Day 3
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - International Shopping List Test (ISL)
Cogstate - International Shopping List (ISL) test is a measure of verbal learning and uses a well-validated list-learning paradigm. Total number of correct responses remembering the word list on three consecutive trials at a single assessment. Higher score is better performance. Higher change from baseline means better performance.
Time frame: Baseline and Hour 3 on Day 3
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - One Card Learning (OCLT).
Cogstate - The One Card Learning Test (OCLT) is a measure of visual learning and uses a well-validated pattern separation paradigm with playing card stimuli. Higher Score is better performance. Higher change from baseline means better performance.
Time frame: Baseline and Hour 3 on Day 3
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Karolinska Sleepiness Scale (KSS).
Scale: 1-9, 1=extremely alert, 9 = very sleepy, great effort to keep awake, fighting sleep
Time frame: Baseline and Hour 3 on Day 3
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Portland Neurotoxicity Scale (PNS).
Portland Neurotoxicity Scale (PNS) comprises 15 questions measured on a 10-point scale. \[1=No problem, 2, 3, 4, 5=Often a problem, 6, 7, 8, 9, 10=Severe problem\] in 16 categories. Each question was analyzed and is presented in the same way as the primary endpoints.
Time frame: Baseline and Hour 3 on Day 3
Change From Baseline Between Gralise® and Neurontin® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).
Miles per Hour (mph)
Time frame: Baseline and Hour 3 on Day 3
Change From Baseline Between Gralise® and Lyrica® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).
Miles per Hour (mph)
Time frame: Baseline and Hour 3 on Day 3
To Compare the Relative Safety and Tolerability of Gralise®, Neurontin®, and Lyrica®.
* Number of subjects with Treatment-Emergent Adverse Events (TEAE) * Number of subjects with Serious Adverse Event (SAE) * Number of subjects discontinued due to Adverse Event (AE)
Time frame: Screening to 1 week after Period 4 discharge
| Milestone | Gral First, Then Neur, Lyr, and Plbo | Neur First, Then Plbo, Gral, and Lyr | Lyr First, Then Gral, Plbo, and Neur | Plbo First, Then Lyr, Neur, and Gral |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 |
| Received gralise® | 8 | 7 | 7 | 6 |
| Received neurontin® | 8 | 8 | 7 | 8 |
| Received lyrica® | 8 | 7 | 8 | 8 |
| Received placebo | 8 | 7 | 7 | 8 |
| Completed | 8 | 7 | 7 | 6 |
| Not completed | 0 | 1 | 1 | 2 |
SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.
| feet | Gralise® (Gabapentin) | Neurontin® (Gabapentin) | Placebo |
|---|---|---|---|
| Change From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Neurontin® | 0.255 ± 0.0781 | 0.395 ± 0.0763 | 0.135 ± 0.0770 |
SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.
| feet | Gralise® (Gabapentin) | Lyrica® (Pregabalin) | Placebo |
|---|---|---|---|
| Change From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Lyrica® | 0.255 ± 0.0781 | 0.356 ± 0.0770 | 0.135 ± 0.0770 |
Cogstate - Detection Task (DET) is a simple reaction time test of Psychomotor Function. Higher change from baseline means better performance.
| msec | Gralise® (Gabapentin) | Neurontin® (Gabapentin) | Lyrica® (Pregabalin) | Placebo (Sugar Pill) |
|---|---|---|---|---|
| Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Detection Task (DET) | 0.00 ± 0.013 | 0.00 ± 0.012 | -0.01 ± 0.012 | -0.00 ± 0.012 |
Cogstate - The Groton Maze Learning test is a measure Executive Function. Total number of errors made while attempting to learn the same hidden pathway across the consecutive learning trials performed at a single assessment. Lower score means better performance. Higher change from baseline means better performance.
| Number of errors on test | Gralise® (Gabapentin) | Neurontin® (Gabapentin) | Lyrica® (Pregabalin) | Placebo (Sugar Pill) |
|---|---|---|---|---|
| Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Groton Maze Learning Test (GMLT). | -0.40 ± 2.484 | -0.01 ± 2.385 | -0.64 ± 2.419 | 3.32 ± 2.420 |
Cogstate - Identification Task (IDN) assesses Attention. Score is speed of performance (mean of the log10 transformed reaction times for correct responses). Lower score (quicker speed) is better performance. Higher change from baseline means better performance.
| Score on Scale | Gralise® (Gabapentin) | Neurontin® (Gabapentin) | Lyrica® (Pregabalin) | Placebo (Sugar Pill) |
|---|---|---|---|---|
| Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Identification Task (IDN). | -0.00 ± 0.000 | 0.00 ± 0.000 | -0.00 ± 0.000 | 0.01 ± 0.000 |
Cogstate - International Shopping List (ISL) test is a measure of verbal learning and uses a well-validated list-learning paradigm. Total number of correct responses remembering the word list on three consecutive trials at a single assessment. Higher score is better performance. Higher change from baseline means better performance.
| Score on Scale | Gralise® (Gabapentin) | Neurontin® (Gabapentin) | Lyrica® (Pregabalin) | Placebo (Sugar Pill) |
|---|---|---|---|---|
| Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - International Shopping List Test (ISL) | 0.36 ± 0.684 | 0.82 ± 0.648 | 0.03 ± 0.660 | -0.01 ± 0.660 |
Cogstate - The One Card Learning Test (OCLT) is a measure of visual learning and uses a well-validated pattern separation paradigm with playing card stimuli. Higher Score is better performance. Higher change from baseline means better performance.
| Score on Scale | Gralise® (Gabapentin) | Neurontin® (Gabapentin) | Lyrica® (Pregabalin) | Placebo (Sugar Pill) |
|---|---|---|---|---|
| Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - One Card Learning (OCLT). | 0.02 ± 0.021 | 0.06 ± 0.020 | 0.00 ± 0.020 | 0.03 ± 0.020 |
Scale: 1-9, 1=extremely alert, 9 = very sleepy, great effort to keep awake, fighting sleep
| units on a scale | Gralise® (Gabapentin) | Neurontin® (Gabapentin) | Lyrica® (Pregabalin) | Placebo (Sugar Pill) |
|---|---|---|---|---|
| Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Karolinska Sleepiness Scale (KSS). | .774 ± .2985 | .264 ± .2876 | .868 ± .2913 | .264 ± .2914 |
Portland Neurotoxicity Scale (PNS) comprises 15 questions measured on a 10-point scale. \[1=No problem, 2, 3, 4, 5=Often a problem, 6, 7, 8, 9, 10=Severe problem\] in 16 categories. Each question was analyzed and is presented in the same way as the primary endpoints.
| scores on a scale | Gralise® (Gabapentin) | Neurontin® (Gabapentin) | Lyrica® (Pregabalin) | Placebo (Sugar Pill) |
|---|---|---|---|---|
| Vision (blurring, double vision) | 0.036 ± 0.1274 | 0.322 ± 0.1235 | 0.249 ± 0.1249 | 0.115 ± 0.1249 |
| Energy Level (get up and go) | 0.099 ± 0.1811 | 0.256 ± 0.1743 | 0.315 ± 0.1766 | 0.331 ± 0.1766 |
| Memory (ability to remember people, places, or thi | 0.077 ± 0.1498 | 0.123 ± 0.1441 | 0.125 ± 0.1460 | -0.041 ± 0.1460 |
| Walking (balance) | 0.206 ± 0.1245 | 0.327 ± 0.1187 | 0.405 ± 0.1206 | 0.107 ± 0.1206 |
| Interest (in activities) | 0.046 ± 0.1174 | 0.030 ± 0.1130 | 0.096 ± 0.1145 | 0.070 ± 0.1145 |
| Coordination | 0.180 ± 0.1338 | 0.392 ± 0.1289 | 0.350 ± 0.1306 | 0.218 ± 0.1306 |
| Tremor (shakiness) | -0.103 ± 0.0571 | 0.037 ± 0.0555 | -0.031 ± 0.0556 | 0.068 ± 0.0556 |
| Concentration (ability to concentrate on a task) | 0.080 ± 0.1205 | 0.164 ± 0.1148 | 0.137 ± 0.1166 | 0.182 ± 0.1166 |
| Speech (slurring words) | 0.035 ± 0.0516 | 0.133 ± 0.0493 | 0.065 ± 0.0501 | 0.103 ± 0.0501 |
| Forgetfulness | 0.118 ± 0.1128 | 0.227 ± 0.1083 | 0.175 ± 0.1098 | 0.079 ± 0.1099 |
| Sleepiness (fatigue, sedation, tiredness) | 0.693 ± 0.2928 | 0.635 ± 0.2802 | 1.176 ± 0.2843 | 0.541 ± 0.2844 |
| Moodiness | 0.181 ± 0.1174 | 0.163 ± 0.1144 | 0.098 ± 0.1155 | 0.100 ± 0.1155 |
| Alertness | 0.297 ± 0.1854 | 0.451 ± 0.1786 | 0.607 ± 0.1809 | 0.353 ± 0.1809 |
| Attention Span | 0.020 ± 0.1115 | 0.133 ± 0.1070 | 0.146 ± 0.1085 | 0.015 ± 0.1085 |
| Motivation | 0.185 ± 0.1338 | 0.232 ± 0.1294 | 0.368 ± 0.1309 | 0.271 ± 0.1309 |
Miles per Hour (mph)
| mph | Gralise® (Gabapentin) | Neurontin® (Gabapentin) | Placebo |
|---|---|---|---|
| Change From Baseline Between Gralise® and Neurontin® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS). | 0.831 ± 0.4844 | 0.947 ± 0.4648 | 0.851 ± 0.4715 |
Miles per Hour (mph)
| mph | Gralise® (Gabapentin) | Lyrica® (Pregabalin) | Placebo |
|---|---|---|---|
| Change From Baseline Between Gralise® and Lyrica® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS). | 0.831 ± 0.4844 | 1.319 ± 0.4713 | 0.851 ± 0.4715 |
* Number of subjects with Treatment-Emergent Adverse Events (TEAE) * Number of subjects with Serious Adverse Event (SAE) * Number of subjects discontinued due to Adverse Event (AE)
| participants | Gralise® (Gabapentin) | Neurontin® (Gabapentin) | Lyrica® (Pregabalin) | Placebo (Sugar Pill) |
|---|---|---|---|---|
| Subjects with TEAE | 6 | 13 | 16 | 5 |
| Subjects with SAE | 0 | 0 | 0 | 0 |
| Subjects Discontinued due to AE | 0 | 1 | 1 | 0 |
Collected over 7 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gralise® (Gabapentin) | — | 0/28 (0%) | 6/28 (21.4%) |
| Neurontin® (Gabapentin) | — | 0/31 (0%) | 11/31 (35.5%) |
| Lyrica® (Pregabalin) | — | 0/31 (0%) | 14/31 (45.2%) |
| Placebo (Sugar Pill) | — | 0/30 (0%) | 2/30 (6.7%) |
| Event | Gralise® (Gabapentin) | Neurontin® (Gabapentin) | Lyrica® (Pregabalin) | Placebo (Sugar Pill) |
|---|---|---|---|---|
| SomnolenceNervous system disorders | 3/28 | 7/31 | 4/31 | 1/30 |
| DizzinessNervous system disorders | 3/28 | 4/31 | 6/31 | 0/30 |
| HeadacheNervous system disorders | 1/28 | 0/31 | 5/31 | 1/30 |
| Euphoric moodPsychiatric disorders | 1/28 | 2/31 | 3/31 | 0/30 |
| Age, Continuous(years) | Gral First, Then Neur, Lyr, and Plbo | Neur First, Then Plbo, Gral, and Lyr | Lyr First, Then Gral, Plbo, and Neur | Plbo First, Then Lyr, Neur, and Gral | Total |
|---|---|---|---|---|---|
| Mean | 49.0 ± 5.32 | 47.6 ± 5.29 | 51.0 ± 9.35 | 46.8 ± 4.06 | 48.6 ± 6.23 |
| Sex: Female, Male(Participants) | Gral First, Then Neur, Lyr, and Plbo | Neur First, Then Plbo, Gral, and Lyr | Lyr First, Then Gral, Plbo, and Neur | Plbo First, Then Lyr, Neur, and Gral | Total |
|---|---|---|---|---|---|
| Female | 1 | 3 | 3 | 1 | 8 |
| Male | 7 | 5 | 5 | 7 | 24 |
No study locations are listed for this record.
Ran from Sep 2015 to primary completion in Nov 2015, 1 month.
Results were first posted in May 2020, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gabapentin · Pregabalin
Depomed